ANN ARBOR, Mich., May 25, 2022 – Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that two new health system partners have joined the Strata Precision Indications for Approved THerapies (Strata PATH^TM) trial. The University of Wisconsin Carbone Cancer Center and the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham will join Ohio-based Kettering Health Cancer Center in bringing this innovative trial to both early-stage and late-stage patients with cancer.

Strata PATH is a prospective pan-tumor therapeutic trial designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies in new, biomarker-guided patient populations. A range of therapeutic classes will be evaluated, including targeted therapies, antibody-drug conjugates, immunotherapies, and angiogenesis inhibitors.

“The Strata PATH trial leverages our novel quantitative RNA and multivariate algorithms to optimize and expand the use of cancer medicines across therapeutic classes,” said Dan Rhodes, Ph.D., co-founder and Chief Executive Officer, Strata Oncology. “We welcome the addition of our new partners and look forward to working with our ever-growing network of researchers to give each patient their optimal biomarker-matched therapy as early as possible.”

Patients interested in learning more about the Strata PATH trial can visit ClinicalTrials.gov and search for the Strata PATH Trial identifier: NCT05097599.